# Efficacy and Safety of Switching to Vemliver From Entecavir in Chronic Hepatitis B Patients Previously Treated With Entecavir

> **NCT06000657** · PHASE4 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 196 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** Vemliver tablet
- **DRUG:** Baracross Tablet

## Key facts

- **NCT ID:** NCT06000657
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-28
- **Primary completion:** 2025-02-03
- **Final completion:** 2025-02-03
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2025-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06000657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06000657, "Efficacy and Safety of Switching to Vemliver From Entecavir in Chronic Hepatitis B Patients Previously Treated With Entecavir". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06000657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*